Mylan N.V. recently released a statement in response to a Financial Times article entitled “HIV/Aids drug for developing world face threat of disruption.”
“We at Mylan were very concerned by Mr. [Brian] Elliott’s piece, given its potential to cause unnecessary confusion within the HIV/AIDS community and to alarm the patients we serve. We would like to take this opportunity to address the fallacies and erroneous conclusions stated by Mr. Elliott,” Mylan wrote in its statement.
Mylan noted that it is one of the leading generic pharmaceutical companies in the world, and its production and supply of high-quality antiretroviral (ARV) medicines is not under threat of production disruption.
“The suggestion by Mr. Elliott that Mylan facilities are at risk of halting production of ARVs and that 7 million patients might lose access to these life-saving drugs is simply untrue,” Mylan wrote.
Additionally, Mylan claimed that the author of the piece did not accurately analyze the ARV market. The company believes that the fact that four companies supply the bulk of ARVs in developing countries does not necessarily suggest that the risk of supply interruption is worrying. The company also believes that bulk procurement is a process that can provide patients with advantages.
“Mylan remains committed to the fight against HIV/AIDS and looks forward to continuing to serve as a partner to maintain and expand access to treatment for people living with HIV,” the company said.
Alerts Sign-up